DURECT announces NDA acceptance of Indivior's RBP-7000 risperidone monthly depot
DURECT announced that Indivior has reported the FDA has accepted the NDA for RBP-7000. RBP-7000 is an investigational, once-monthly injectable risperidone for treatment of schizophrenia. Indivior further reported the FDA has set a PDUFA target action date of July 28, 2018. December 13, 2017